Multiple cAMP-induced signaling cascades regulate prolactin expression in T cells by unknown
Abstract. Beside its pivotal role in reproduction, the pi-
tuitary hormone prolactin (PRL) has been attributed an
immunomodulatory function. Here we report that cAMP
is an important stimulator of PRL transcription in pri-
mary human T lymphocytes. Inhibition of both protein ki-
nase A (PKA) and p38 MAPK partially abrogated cAMP-
induced PRL expression. In addition, cAMP-induced
phosphorylation of p38 was shown to occur indepen-
dently of PKA and could be mimicked by a methylated
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cAMP analogue which specifically activates the recently
discovered cAMP receptor EPAC (exchange protein di-
rectly activated by cAMP). Our findings suggest that
cAMP induces PRL expression in T lymphocytes via co-
operation of at least two different signaling pathways: a
PKA-dependent pathway leading to the phosphorylation
of cAMP response element-binding protein, and a PKA-
independent pathway leading to p38 phosphorylation.
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The immune system is one of the targets of the polypep-
tide hormone prolactin (PRL). Although PRL is pre-
dominantly produced by the pituitary, the hormone is
also synthesized extrapituitarily by other tissues [1, 2].
In the immune system, expression of the PRL gene has
been demonstrated in human mononuclear cells [3–5]
and was mainly associated with the T lymphocyte popu-
lation [4]. In addition, high-affinity PRL receptors are
expressed on B lymphocytes, T lymphocytes, natural
killer (NK) cells and monocytes [4], suggesting the hor-
mone may act in an autocrine or paracrine, cytokine-like,
fashion in the immune system. There is indeed com-
pelling evidence for in vitro effects of PRL on immune
cell function. For example, PRL stimulates inducible ni-
tric oxide synthetase production [6] and immunoglobu-
lin release [7] in human leukocytes and it has anti-apop-
totic properties in Nb2 rat lymphoma cells [8] and dex-
amethasone-treated thymocytes [9]. PRL was recently
demonstrated to stimulate the maturation of rat [10] and
human [11] dendritic cells. PRL-treated rat dendritic
cells produced increased amounts of interleukin (IL)-12,
tumor necrosis factor (TNF)-alpha and IL-1beta [10].
In addition, several groups have reported stimulatory ef-
fects of PRL on interferon (IFN)-gamma secretion
[12–15]. 
The importance of T lymphocyte-derived PRL is indi-
cated by the observation that PRL is an autocrine growth
factor for human mononuclear cells [3, 16] as well as for
the human leukemic T cell line Jurkat [17]. Hyperpro-
lactinemia, correlating with disease activity, has been
described in autoimmune conditions such as systemic
lupus erythematosus [18] and rheumatoid arthritis [19,
20]. A local or endocrine role for T lymphocyte-derived
PRL in systemic lupus erythematosus is suggested by
enhanced PRL production in T cells from patients com-
pared to normal controls [21, 22]. Furthermore, in pa-
tients with rheumatoid arthritis, PRL, produced by syn-
ovium-infiltrating T-lymphocytes, causes aberrant syn-
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ovial cell function and might thus influence disease pro-
gression [23].
Due to the use of an alternative promoter, located 5.8 kb
upstream of the pituitary PRL promoter, by extrapitu-
itary PRL sources [24, 25], leukocyte PRL expression is
regulated by different signaling pathways and different
hormones, cytokines or neuropeptides when compared
to pituitary PRL expression [2]. We and others have
shown that cAMP is an important stimulator of PRL ex-
pression in leukocytes. Indeed, cAMP stimulates PRL
expression in the T leukemic cell line Jurkat [26–28], in
the eosinophilic leukaemia cell line Eol-1 [27, 29] and in
human peripheral blood mononuclear cells (PBMCs)
[27].
In T lymphocytes, elevation of intracellular cAMP, in-
duced by agents such as prostaglandin E2 (PGE2),
cholera toxin, forskolin or cAMP analogues, inhibits IL-
2 and IL-2 receptor expression, thereby blocking cell cy-
cle progression and proliferation [30–35]. Furthermore,
cAMP inhibits the expression of Th1 cytokines, whereas
it stimulates IL-5 expression by Th2 cells [34, 36, 37].
The classical view is that cAMP exerts its effects via ac-
tivation of the cAMP-dependent protein kinase (PKA),
which subsequently phosphorylates downstream effec-
tors such as CREB [38]. However, PKA-independent ac-
tions of cAMP have been described in several cell types
and evidence for the importance of these PKA-indepen-
dent pathways in the immunomodulatory effects of
cAMP is emerging. For example, the effects of cAMP on
human T cell proliferation [39] and on IL-5 production
by human T lymphocytes [40] were reported to be PKA-
independent. In addition, we recently showed that in the
myeloid leukemic cell line Eol-1, PKA independent
pathways, in addition to the classical pathway involving
activation of PKA and CREB, contribute to cAMP-in-
duced PRL expression [29]. Whereas the alternative
cAMP receptors in these studies remain to be identified,
possible candidates could be the recently identified gua-
nine exchange proteins directly activated by cAMP
(EPAC1 and EPAC2) [41, 42]. Indeed, a recent study in-
dicates that stimulation of EPAC1 inhibits the bacterici-
dal activity of alveolar macrophages, implying that the
protein is involved in regulating the activation of im-
mune cells [43]. 
Since T lymphocyte-derived PRL has been implicated in
normal and pathological immune responses, and cAMP-
induced gene expression in these cells has been relatively
unexplored, we addressed the mechanisms used by cAMP
to induce PRL expression in human T lymphocytes. We
found that cAMP stimulates PRL expression in part
through PKA, and partially through PKA-independent
activation of p38. We provide evidence for the expression
of EPAC1, which may mediate the p38-activating effects
of cAMP in human T lymphocytes.
Materials and methods
Reagents. RMPI-1640 (with glutamax) was purchased
from Life Technologies (Merelbeke, Belgium). BSA,
H89, 8-(4-chloro-phenyl-thio)-cAMP (cptcAMP) and 8-
(4-chloro-phenyl-thio)-2-O-methyl cAMP (Me-cptcAMP)
were purchased from Sigma-Aldrich (St. Louis, M.)
SB203580 was from Biomol (Plymouth, P.). Except for
cptcAMP and Me-cptcAMP, which were dissolved in
LPS-free water (Baxter, Lessines, Belgium), all inhibitors
were dissolved in DMSO. The rabbit antibodies against P-
p38, ERK1/2, P-JNK, JNK, P-CREB and CREB, and the
mouse monoclonal against P-ERK1/2 were obtained from
Cell Signaling (Beverly, Mass.). P-CREB antibody detects
CREB only when phosphorylated at ser133 and this anti-
body also detects the phosphorylated form of CREB-re-
lated protein ATF-1. Rabbit antibodies against p38 were
from Santa Cruz Biotechnology (Santa Cruz, Calif.). Per-
oxidase-conjugated donkey anti-rabbit and sheep anti-
mouse IgGs were obtained from Amersham Pharmacia
Biotech (Roosendaal, The Netherlands). 
Cell preparation and cell culture. Jurkat cells were ob-
tained from the European Collection of Cell Cultures
(Salisbury, UK). T lymphocytes were isolated from buffy
coats obtained from normal donors. First, PBMCs were
isolated by centrifugation on Ficoll-Isopaque (Pharmacia
& Upjohn, Uppsala, Sweden) density gradients (1.077 g/
ml) at 1000 g for 20 min. Subsequently, T lymphocytes
were isolated by sheep red blood cell rosetting [44]. Pu-
rity of the T lymphocyte fraction was always over 90% as
assessed by flow cytometric analysis. T lymphocytes
were resuspended in RPMI-1640 supplemented with 1%
BSA, at a concentration of 5¥106/ml. To measure the
effects of cAMP analogues on PRL mRNA expression,
cells were cultured for 6 h in a humidified 5% CO2 at-
mosphere at 37 °C. To address cAMP-induced protein
phosphorylation, cells were cultured for 20 min in 2-ml
reaction tubes (Eppendorf, Hamburg, Germany) in a wa-
ter bath at 37 °C.
RT-PCR. Isolation of total RNA and reverse transcrip-
tion were performed as described before [45]. Briefly,
for PRL mRNA detection, a real-time cDNA amplifica-
tion was performed using the Applied Biosystems
(Nieuwerkerk a/d IJssel, The Netherlands) Assay-On-
Demand for human prolactin (hs 00168730_m1) and a
five-point standard curve (0.02–200 ng total RNA from
Jurkat cells). This assay uses a specific TaqMan MGB
probe with an FAM reporter dye at the 5¢ end and a non-
fluorescent quencher at the 3¢ end. Fluorescence was
monitored using the Taqman 7700 Sequence detector
(Applied Biosystems). For detection of EPAC1 and
EPAC2 transcripts, cDNA samples were subjected to 35
rounds of PCR cycling (94 °C for 1 min, 50°C for 2 min,
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72 °C for 45 s) using the following primer sets: for
EPAC1: CTTCCTCCAGAAACTCTCAG (sense) and
TCAGCTCATGCGCTTCCTG (antisense); for EPAC2:
CTCATTGAACCTCACGTTCC (sense) and AGT-
CATCTCCTTCATGCAGG (antisense).
Western blotting. Preparation of cellular extracts and
Western blotting were performed as described earlier
[28]. All primary antibodies were used at a 1:1000 dilu-
tion. Before reprobing, blots were stripped by washing in
ddH20 for 10 min, followed by a 5-min incubation in 0.2
M NaOH and another washing in ddH20. 
Statistics. Statistical differences between groups were
determined by ANOVA, followed by Tukey’s post-test.
Data represented are means ± SD of quadruplicate incu-
bations of cells from one donor. The presented experi-
ments are representative of three (figs. 1, 2, 3 and 5) or
eight (fig. 4) independent experiments using different
donors.
Results
cAMP stimulates PRL transcription in primary hu-
man T lymphocytes. We previously showed that cAMP
induces PRL mRNA expression in freshly isolated human
PBMCs and in the human T leukemic cell line Jurkat
[27]. To assess whether cAMP induces PRL expression in
primary T lymphocytes, we investigated the effect of
cAMP on PRL mRNA levels in purified primary human
T lymphocytes. We found that the long-acting cAMP ana-
logue cptcAMP stimulated PRL mRNA levels in primary
T lymphocytes by 12.9 ± 11.2-fold. Whereas PRL mRNA
levels were positively affected by cAMP in all investi-
gated donors (n=12), the size of the response to cAMP
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Figure 1. The effect of cAMP on PRL expression in primary T lymphocytes requires de novo mRNA synthesis. (A) T lymphocytes were prein-
cubated for 1 h with vehicle or the transcriptional inhibitor actinomycin D (5 mg/ml) and next stimulated with vehicle or cptcAMP (250 mM)
for 6 h. PRL mRNA levels were quantified by real-time PCR and normalized to GAPDH mRNA expression. # Significantly different from
control without actinomycin D (p < 0.01). (B) Decay of PRL mRNA levels as measured by real-time PCR. T lymphocytes were preincubated
for 1 h with actinomycin D (5 mg/ml) and next stimulated with vehicle or cptcAMP (250 mM) for 0, 4, 6 and 18 h. PRL mRNA levels are rep-
resented as percentage of control (actinomycin D 5 mg/ml, no cptcAMP at time 0). The results in this figure are obtained from the same donor.
Figure 2. Effect of inhibition of PKA on cAMP-induced PRL
mRNA expression and CREB phosphorylation in human T lym-
phocytes. (A) T lymphocytes were pretreated for 2 h with vehicle,
H89 (10 mM) or SB203580 (50 mM), before stimulation with 250
mM cptcAMP for 6 h. PRL mRNA levels were quantified by real-
time PCR and normalized to GAPDH mRNA expression. Control
conditions are always significantly different from corresponding
cptcAMP-stimulated conditions (p<0.01). (B) T lymphocytes were
preincubated for 2 h with increasing doses of H89, before stimula-
tion with cptcAMP (250 mM) for 20 min. P-CREB and total CREB
were monitored by western blotting. The results in the figure are ob-
tained from the same donor. 
was very much donor dependent, with a 34.7-fold induc-
tion in the best responder versus only a 3.6-fold induction
in the weakest responder. As shown in figure 1A, prein-
cubation of primary T lymphocytes with the transcrip-
tional inhibitor actinomycin D completely blocked the ef-
fect of cptcAMP on PRL mRNA expression. In addition,
cptcAMP did not affect the rate of decay of the PRL mes-
sage in T cells treated with actinomycin D (fig. 1B), indi-
cating that cAMP enhances PRL expression in primary T
lymphocytes by stimulating transcription.
cAMP-induced PRL expression is partially mediated
via PKA in primary human T lymphocytes. PKA is the
best-known effector of cAMP signaling. We therefore in-
vestigated the effect of PKA inhibition, using H89, on
cAMP-induced PRL expression in primary T lympho-
cytes. Figure 2A shows that, at maximal subcytotoxic
doses (10 mM), H89 only partially blocked cptcAMP-in-
duced PRL expression, whereas it completely abolished
cptcAMP-induced phosphorylation of the principal PKA
target, CREB (fig. 2B).
Role of MAPKs in cAMP-induced PRL expression. In
leukocytes and other cell types, cAMP has been shown to
mediate some of its effects via activation or inhibition of
MAPK pathways [46]. Therefore, since inhibition of
PKA did not completely block cAMP-induced expres-
sion, we addressed the effect of cptcAMP on activation
of p38, ERK and JNK. We found that ERK and JNK
phosphorylation were undetectable both in unstimulated
and cptcAMP-stimulated T lymphocytes (fig. 3A), but
could be induced by 12-O-tetradecanoyl-phorbol-13-ac-
etate (TPA) and anisomycin respectively (data not
shown). However, cptcAMP dose dependently stimulated
p38 phosphorylation (fig. 3B). To address the role of
PKA in the effect of cAMP on p38 activation, we investi-
gated the effect of H89 on the phosphorylation of p38. As
shown in figure 3C, H89 did not affect cptcAMP-induced
p38 phosphorylation, indicating cptcAMP phosphory-
lates p38 in a PKA-independent manner. 
The role of the p38 MAPK in the effect of cptcAMP on
PRL expression in T lymphocytes was indicated by the
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Figure 3. Effect of cAMP on MAPK activation in human T lym-
phocytes and role of PKA in this effect. Cells were stimulated for
20 min with the indicated doses of cptcAMP. MAPK activation was
assessed by Western blotting. (A) P-ERK, ERK, P-JNK and JNK in
T lymphocytes stimulated with 250 mM of cptcAMP. (B) P-p38 and
total p38 in T lymphocytes stimulated with increasing doses (25,
250 and 500 mM) of cptcAMP. (C) P-p38 and total p38 in T lym-
phocytes preincubated for 2 h with increasing doses of H89, before
stimulation with cptcAMP (250 mM). The results in A–C are ob-
tained from three different donors. The results in B are obtained
from the same donor as in figure 5A. 
Figure 4. Expression of EPAC1 in primary T lymphocytes. Detec-
tion of EPAC1 mRNA by RT-PCR in human PBMC, T cell and non-
T cell samples. EPAC1 expression was detected in T cells from all
eight donors tested. Results are shown for three representative
donors. Lanes 1, 4, 7: PBMC; lanes 2, 5, 8: T cells; lanes 3, 6, 9:
non-T cells.
Figure 5. Role of EPAC in the effects of cAMP on PRL expression
in human T lymphocytes. (A) T cells were stimulated for 20 min
with increasing doses (25, 250 and 500 mM) of Me-cptcAMP. Acti-
vation of p38 was assessed by Western blotting. (B) T lymphocytes
were stimulated for 6 h with increasing doses of cptcAMP or Me-
cptcAMP. PRL mRNA levels were quantified by real-time PCR and
normalized to GAPDH mRNA expression. (C) P-p38 and total p38
as assessed by Western blotting in Jurkat cells stimulated for 20 min
with vehicle or 250 mM of cptcAMP. The results in A and B are ob-
tained from two different donors. The results in A are obtained from
the same donor as figure 3B.
finding that SB203580, a specific p38 inhibitor, partially
abolished the effect of cptcAMP on PRL expression
(fig. 2A). 
Role of EPAC in PRL expression in human T lympho-
cytes. Whereas PKA is the best-known mediator of
cAMP effects, recently, the activation of alternative,
PKA-independent, signaling routes through EPAC by
cAMP have been described. We therefore addressed the
expression of the novel cAMP receptors EPAC1 and
EPAC2 by RT-PCR in primary T lymphocytes of eight
donors. EPAC1 transcripts were amplified from cDNA
samples obtained from PBMCs and T cells (as well as
from the residual non-T cell fraction) from all donors
(n=8) (fig. 4). The PCR product identity was confirmed
by DNA sequencing. EPAC2 transcripts were unde-
tectable in all samples (data not shown). Using a methy-
lated cptcAMP analogue, which is unable to activate
PKA, but instead specifically activates EPAC [47], we in-
vestigated the role of EPAC in regulating PRL expression
in T cells. As shown in figure 5A, Me-cptcAMP stimu-
lated p38 activity in T lymphocytes, whereas it did not af-
fect CREB phosphorylation (data not shown). However,
unlike cptcAMP, which dose dependently stimulated PRL
mRNA levels in human T lymphocytes, Me-cptcAMP
had no effect on PRL expression (fig. 5B). We previously
demonstrated that the stimulatory effect of cptcAMP on
PRL expression in the human T leukemic cell line Jurkat
is mediated by PKA only [28]. Indeed, as depicted in fig-
ure 5C, in these cells, cptcAMP did not induce p38 phos-
phorylation.
Discussion
We and others previously showed that cAMP and factors
signaling via cAMP, such as PGE2, stimulate PRL ex-
pression through the extrapituitary promoter in human
PBMCs and in the human T leukemic cell line Jurkat
[26–28]. Here we show that cAMP is also a potent in-
ducer of PRL transcription in primary T lymphocytes.
Although cAMP increased PRL expression in all 12
donors tested, there was a large variation in the strength
of the response. Since in vitro stimulation of PRL ex-
pression by phytohemagglutinin has been shown to re-
late to a single nucleotide polymorphisms at –1149 of
the lymphoid promoter [48], the possibility exists that
this polymorphism causes a variation in the strength of
the cAMP effect on PRL expression. Interestingly, this
polymorphism was prevalent in patients with systemic
lupus erythematosus. PGE2 and other factors that signal
through cAMP, such as catecholamines, usually inhibit
Th1 responses [49, 50], whereas PRL predominantly
stimulates expression of Th1 cytokines [10, 12–15, 51].
Since endogenous PRL has especially been shown to
have immunomodulatory effects in animals subjected to
stress [52, 53], one can speculate that induction of PRL
expression in the immune system serves as a feedback
mechanism to restrict the effect of stress hormones on
the immune system. This hypothesis could be tested by
assessing the effects of catecholamines in the absence
and in the presence of inhibiting antibodies against PRL.
Indeed, autocrine or paracrine effects of small amounts
of PRL secreted by PBMCs have been shown in several
studies [3, 54]. 
According to the classical paradigm, cAMP modulates
gene transcription via activation of PKA and subsequent
phosphorylation of CREB [38]. However, some of the
effects of cAMP on T lymphocytes have been shown to
be PKA independent. For example, in a murine Th2 cell
line [55] and in human PBMCs [40], the effects of
cAMP on IL-5 expression were PKA independent. Here
we show that in human T lymphocytes, cAMP stimu-
lates PRL gene expression via activation of both PKA-
dependent and PKA-independent signaling pathways.
The PKA inhibitor H89 completely blocked phosphory-
lation of CREB at Ser133, yet failed to completely in-
hibit cAMP-induced PRL gene transcription, suggest-
ing that other kinases and transcription factors, beside
PKA and CREB are involved in the effect of cAMP on
PRL expression. Our observation that cAMP induced
p38 activation, whereas a specific p38 inhibitor,
SB203580, partially inhibited cAMP-induced-PRL ex-
pression in T lymphocytes, indicates p38 is one of the
kinases that are activated by cAMP, in addition to PKA.
Only a few studies have described effects of cAMP me-
diated by p38. For example, cAMP induces p38 activa-
tion in Chinese hamster ovary cells [56], in murine car-
diomyocytes [57], macrophages [58] and Th2 cells [55],
in rat granulosa cells [59] and in human SK-N-MC neu-
roblastoma cells [60]. Interestingly, whereas in most of
these studies the effect of cAMP on p38 activation was
PKA dependent, this was not the case in the murine Th2
cells [55]. Our results indicate that in normal human T
lymphocytes, p38 is also activated independently of
PKA. Whereas the signaling intermediate(s) activated
by cAMP and responsible for the observed p38 activa-
tion remain to be identified, the findings that the EPAC
activator Me-cptcAMP also stimulates p38 phosphory-
lation, and that primary T lymphocytes express EPAC1
transcripts, suggest a possible candidate could be the re-
cently identified small guanine nucleotide exchange
factor EPAC1. EPAC1 transcripts have only been de-
tected in B lymphocytes [61] and alveolar macrophages
[43] but not in other leukocyte subpopulations. Whereas
Tiwari et al. [61] were unable to detect EPAC1 or
EPAC2 by RT-PCR in human T lymphocytes, we did de-
tect messages for the EPAC1 gene by RT-PCR in human
T cells. Since, to date, no specific inhibitors for EPAC
activity are available, proving that EPAC is indeed re-
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sponsible for the effect of cAMP on p38 activation is
very difficult. In addition, it has been suggested that in
human T cells the cAMP-induced, but PKA-indepen-
dent, pathway leading to inhibition of IL-5 does not in-
volve EPAC [40], indicating another, unidentified, sig-
naling protein, which is activated by Me-cptcAMP as
well as by cptcAMP, could be responsible for the ob-
served p38 activation. 
Our observation that cAMP is able to stimulate some
PRL expression in the presence of H89, which com-
pletely blocks CREB phosphorylation, indicates that a
PKA-independent pathway is also involved in PRL ex-
pression, and that this pathway is operative in the absence
of PKA activity. Indeed, inhibition of p38 also partially
blocked induction of PRL expression. However, activa-
tion by Me-cptcAMP of p38 without PKA activation was
not sufficient to enhance PRL expression. These obser-
vations suggest that cAMP induces a third, unidentified,
route that stimulates PRL expression in human T lym-
phocytes. The p38 route probably acts in synergy with
this unidentified route to enhance PRL transcription. In
leukemic Jurkat T lymphocytes, full induction of PRL
transcription has previously been demonstrated to require
costimulatory signals, which can come from either the
PKC-activating phorbolester TPA or the Ca2+ ionophore
ionomycin [26, 27], in addition to the cAMP stimulus.
These synergistic effects were not observed in normal hu-
man PBMCs, where cAMP potently induced PRL ex-
pression by itself [27]. We speculate that in human T lym-
phocytes, cAMP does not require a costimulus to induce
PRL expression, because it induces at least one PKA-in-
dependent pathway, leading to p38 activation, in addition
to the well-known PKA pathway. Interestingly, the p38
pathway was indeed not activated by cAMP in Jurkat
cells (fig. 5C) but was also activated in the Eol-1 cell line
[29]. In these cells, as in T lymphocytes, cAMP by itself
is a potent inducer of PRL expression. 
Whereas pituitary PRL overproduction can be effec-
tively treated using dopamine agonists, leukocyte PRL
expression is directed by an alternative promoter and is
independent from the factors regulating pituitary PRL
expression. T lymphocyte-derived PRL has been impli-
cated in the pathophysiology of auto-immune disease
and further research on the signaling routes leading to
PRL expression in T lymphocytes may be of clinical im-
portance. This paper and earlier publications from us and
other groups indicate that cAMP is an important regula-
tor of leukocyte PRL expression. Whereas our find-
ings suggest that the PKA pathway is important in this
process, at least one additional signal transmitted via p38
is required for full PRL induction in T lymphocytes.
Importantly, we have detected the novel cAMP receptor
EPAC1 in primary T lymphocytes and hypothesize that
EPAC1 could be the signaling intermediate linking
cAMP to p38. 
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